Sign In
Buy AMN
AMN Healthcare Services Earnings Calls
| Release date | May 07, 2026 |
| EPS estimate | $1.60 |
| EPS actual | $2.10 |
| EPS Surprise | 31.25% |
| Revenue estimate | 1.234B |
| Revenue actual | 1.378B |
| Revenue Surprise | 11.74% |
| Release date | Feb 19, 2026 |
| EPS estimate | $0.220 |
| EPS actual | $0.220 |
| Revenue estimate | 723.704M |
| Revenue actual | 748.225M |
| Revenue Surprise | 3.39% |
| Release date | Nov 06, 2025 |
| EPS estimate | $0.190 |
| EPS actual | $0.390 |
| EPS Surprise | 105.26% |
| Revenue estimate | 723.121M |
| Revenue actual | 634.496M |
| Revenue Surprise | -12.26% |
| Release date | Aug 07, 2025 |
| EPS estimate | $0.170 |
| EPS actual | $0.300 |
| EPS Surprise | 76.47% |
| Revenue estimate | 639.642M |
| Revenue actual | 658.175M |
| Revenue Surprise | 2.90% |
Last 4 Quarters for AMN Healthcare Services
Below you can see how AMN performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 07, 2025 |
| Price on release | $16.92 |
| EPS estimate | $0.170 |
| EPS actual | $0.300 |
| EPS surprise | 76.47% |
| Date | Price |
|---|---|
| Aug 01, 2025 | $17.85 |
| Aug 04, 2025 | $17.43 |
| Aug 05, 2025 | $17.49 |
| Aug 06, 2025 | $17.22 |
| Aug 07, 2025 | $16.92 |
| Aug 08, 2025 | $17.24 |
| Aug 11, 2025 | $16.49 |
| Aug 12, 2025 | $17.64 |
| Aug 13, 2025 | $18.64 |
| 4 days before | -5.21% |
| 4 days after | 10.17% |
| On release day | 1.89% |
| Change in period | 4.43% |
| Release date | Nov 06, 2025 |
| Price on release | $18.43 |
| EPS estimate | $0.190 |
| EPS actual | $0.390 |
| EPS surprise | 105.26% |
| Date | Price |
|---|---|
| Oct 31, 2025 | $19.69 |
| Nov 03, 2025 | $19.58 |
| Nov 04, 2025 | $19.70 |
| Nov 05, 2025 | $20.63 |
| Nov 06, 2025 | $18.43 |
| Nov 07, 2025 | $17.87 |
| Nov 10, 2025 | $17.31 |
| Nov 11, 2025 | $16.85 |
| Nov 12, 2025 | $16.59 |
| 4 days before | -6.40% |
| 4 days after | -9.98% |
| On release day | -3.04% |
| Change in period | -15.74% |
| Release date | Feb 19, 2026 |
| Price on release | $17.28 |
| EPS estimate | $0.220 |
| EPS actual | $0.220 |
| Date | Price |
|---|---|
| Feb 12, 2026 | $16.26 |
| Feb 13, 2026 | $16.25 |
| Feb 17, 2026 | $16.39 |
| Feb 18, 2026 | $17.08 |
| Feb 19, 2026 | $17.28 |
| Feb 20, 2026 | $19.32 |
| Feb 23, 2026 | $20.81 |
| Feb 24, 2026 | $20.40 |
| Feb 25, 2026 | $20.01 |
| 4 days before | 6.27% |
| 4 days after | 15.80% |
| On release day | 11.81% |
| Change in period | 23.06% |
| Release date | May 07, 2026 |
| Price on release | $22.45 |
| EPS estimate | $1.60 |
| EPS actual | $2.10 |
| EPS surprise | 31.25% |
| Date | Price |
|---|---|
| May 01, 2026 | $21.12 |
| May 04, 2026 | $20.72 |
| May 05, 2026 | $21.28 |
| May 06, 2026 | $20.97 |
| May 07, 2026 | $22.45 |
| May 08, 2026 | $28.97 |
| May 11, 2026 | $30.27 |
| May 12, 2026 | $29.47 |
| May 13, 2026 | $30.87 |
| 4 days before | 6.30% |
| 4 days after | 37.51% |
| On release day | 29.04% |
| Change in period | 46.16% |
AMN Healthcare Services Earnings Call Transcript Summary of Q1 2026
AMN Healthcare reported a strong Q1 2026 with consolidated revenue of $1.38B (above guidance), adjusted EBITDA of $166M (12.1% margin), and gross margin of 26.8%. The quarter was driven by unusually large labor-disruption activity ($722M) and related rapid-response placements, which boosted bill rates and volume in Nurse & Allied Solutions (segment revenue $1.13B; travel nurse revenue +13% YoY ex-disruption). International staffing and leadership search returned to YoY growth. Physician & Leadership Solutions and Technology & Workforce Solutions remain challenged with softer locum demand and language-services mix/pricing pressure, though language-services margins improved sequentially after a service-model rollout. AMN executed large-scale deployments that validated recent technology and AI investments (event management, AI recruitment, AMN Passport, WorkWise enhancements). Balance sheet improved: cash $551M (temporary client deposits largely expected to be refunded), total debt $750M and leverage 1.6x. Q2 guidance: consolidated revenue $620M–$635M, gross margin ~28%–28.5%, adjusted EBITDA margin 6.7%–7.2%, and an operating margin around -0.6% to +0.1%. Management emphasized continued focus on scaling tech-enabled operations, improving fill rates (including AI-enabled recruiting), margin recovery in TWS, and a longer-term objective to drive adjusted EBITDA growth at roughly 2x revenue growth as core businesses normalize.
